Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
A review and comparison of methods for recreating individual patient data from published Kaplan-Meier survival curves for economic evaluations: a simulation study
X Wan, L Peng, Y Li - PLoS One, 2015 - journals.plos.org
Background In general, the individual patient-level data (IPD) collected in clinical trials are
not available to independent researchers to conduct economic evaluations; researchers …
not available to independent researchers to conduct economic evaluations; researchers …
Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients
Background: Spinal muscular atrophy type 1 (SMA1) is a devastating genetic disease for
which gene-replacement therapy may bring substantial survival and quality of life benefits …
which gene-replacement therapy may bring substantial survival and quality of life benefits …
Cost-Effectiveness Analysis of Camrelizumab vs. Placebo Added to Chemotherapy as First-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell …
Q Zhang, P Wu, X He, Y Ding, Y Shu - Frontiers in oncology, 2021 - frontiersin.org
Objective The purpose of this cost-effectiveness analysis was to estimate the effects of
adding camrelizumab to standard chemotherapy as the first-line treatment in patients with …
adding camrelizumab to standard chemotherapy as the first-line treatment in patients with …
Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma
Follicular lymphoma (FL) is traditionally considered treatable but incurable. In March 2021,
the US Food and Drug Administration approved the use of chimeric antigen receptor (CAR) …
the US Food and Drug Administration approved the use of chimeric antigen receptor (CAR) …
Pembrolizumab combined with chemotherapy versus placebo combined with chemotherapy for HER2-negative advanced gastric cancer in China: a cost-effectiveness …
Z Zheng, X Song, H Cai, H Zhu - Expert Review of …, 2024 - Taylor & Francis
Objective This study aims to conduct a cost-effectiveness analysis of pembrolizumab in
combination with chemotherapy for HER2-negative advanced gastric cancer in China …
combination with chemotherapy for HER2-negative advanced gastric cancer in China …
Projecting the 10-year costs of care and mortality burden of depression until 2032: a Markov modelling study developed from real-world data
VKY Chan, MYM Leung, SSM Chan, D Yang… - The Lancet Regional …, 2024 - thelancet.com
Background Based on real-world data, we developed a 10-year prediction model to estimate
the burden among patients with depression from the public healthcare system payer's …
the burden among patients with depression from the public healthcare system payer's …
Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
J Yang, J Han, Y Zhang, M Muhetaer… - Frontiers in …, 2022 - frontiersin.org
Background: The DESTINY-Breast03 clinical trial demonstrated that trastuzumab deruxtecan
(T-DXd) outperformed trastuzumab emtansine (T-DM1) in progression-free survival (PFS) in …
(T-DXd) outperformed trastuzumab emtansine (T-DM1) in progression-free survival (PFS) in …
Cost-effectiveness analysis of gene-based therapies for patients with spinal muscular atrophy type I in Australia
Introduction Spinal muscular atrophy (SMA) is an inherited neuromuscular disorder and
regarded as one of the most frequent genetic causes of infant mortality. The aim of this study …
regarded as one of the most frequent genetic causes of infant mortality. The aim of this study …
Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia
The ALLIANCE A041202 trial found that continuously administered ibrutinib in the first-line
setting significantly prolonged progression-free survival compared with a fixed-duration …
setting significantly prolonged progression-free survival compared with a fixed-duration …
Cost-effectiveness analysis of camrelizumab versus chemotherapy as second-line treatment of advanced or metastatic esophageal squamous cell carcinoma
H Cai, B Xu, N Li, B Zheng, Z Zheng… - Frontiers in pharmacology, 2021 - frontiersin.org
Background: This study aimed to analyze the cost effectiveness of camrelizumab in the
second-line treatment of advanced or metastatic esophageal squamous cell carcinoma in …
second-line treatment of advanced or metastatic esophageal squamous cell carcinoma in …